Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies-Reference-Cited by-同舟云学术

Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies

Published:2015-11-19 Issue:21 Volume:126 Page:2392-2403
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Matthews Geoffrey M.¹²,Mehdipour Parinaz³,Cluse Leonie A.¹²,Falkenberg Katrina J.¹⁴⁵,Wang Eric⁶,Roth Mareike⁴,Santoro Fabio³,Vidacs Eva¹²,Stanley Kym¹²,House Colin M.²,Rusche James R.⁷,Vakoc Christopher R.⁶,Zuber Johannes⁴,Minucci Saverio³⁸⁹,Johnstone Ricky W.¹²

Affiliation:

1. Cancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia;

2. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia;

3. Department of Experimental Oncology, European Institute of Oncology, Milan, Italy;

4. Research Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria;

5. Department of Pathology, University of Melbourne, Parkville, Victoria, Australia;

6. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY;

7. Repligen Corporation, Waltham, MA;

8. Drug Development Program, European Institute of Oncology, Milan, Italy; and

9. Department of Biosciences, University of Milan, Milan, Italy

Abstract

Key Points Genetic studies suggest HDAC3-selective suppression may prove useful for treatment of hematological tumors but will not induce apoptosis. Genetic and pharmacological cosuppression of HDAC1 with HDAC2 induces a potent pro-apoptotic response of tumor cells.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/21/2392/1390054/2392.pdf

Reference64 articles.

1. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.;Falkenberg;Nat Rev Drug Discov,2014

2. New and emerging HDAC inhibitors for cancer treatment.;West;J Clin Invest,2014

3. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes.;Bantscheff;Nat Biotechnol,2011

4. Cancer epigenetics: from mechanism to therapy.;Dawson;Cell,2012

5. Class I HDACs affect DNA replication, repair, and chromatin structure: implications for cancer therapy.;Stengel;Antioxid Redox Signal,2015

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Marine Cytotoxin Santacruzamate A Derivatives as Potent HDAC1-3 Inhibitors and Their Synergistic Anti-Leukemia Effects with Venetoclax;Marine Drugs;2024-05-28

2. Histone deacetylase inhibitor pracinostat suppresses colorectal cancer by inducing CDK5-Drp1 signaling-mediated peripheral mitofission;Journal of Pharmaceutical Analysis;2023-10

3. Collateral lethality between HDAC1 and HDAC2 exploits cancer-specific NuRD complex vulnerabilities;Nature Structural & Molecular Biology;2023-07-24

4. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα;Cell Death & Differentiation;2023-03-09

5. Applying CRISPR-Cas9 screens to dissect hematological malignancies;Blood Advances;2022-11-10